Underlying comorbidity reveals unique immune signatures 1 in Type II diabetes patients infected with SARS-CoV2 2

Soumya Sengupta ^{1,2†}, Gargee Bhattacharya ^{1,2†}, Sanchari Chatterjee^{1,2}, Ankita Datey^{1,3}, 3 Shubham K Shaw^{1,2}, Sandhya Suranjika¹, Paritosh Nath¹, Prakash K Barik¹, Punit Prasad^{1,2}, 4 Soma Chattopadhyay^{1,2}, Rajeeb K Swain^{1,2*} Ajay Parida^{1,2*}, Satish Devadas^{1,2*} 5

- 6 1 Institute of Life Science, Nalco Square, Bhubaneswar, Odisha, India-751023.
- 7 2 Regional Centre for Biotechnology (RCB), 3rd Milestone, Faridabad-Gurgaon, Haryana-121001,
- 8 India
- 3 School of Biotechnology, Kalinga Institute of Industrial Technology (KIIT) University, 9
- Bhubaneswar, Odisha, India-751024. 10
- 11 [†]These authors contributed equally
- *Address of Corresponding authors: 12
- Dr Rajeeb K Swain (RS) 13
- 14 Cancer Biology,
- Institute of Life Sciences 15
- 16 (Autonomous Institute of Dept of Biotechnology, Govt. of India),
- 17 Nalco Square, Bhubaneswar-751023. Odisha, India
- Phone No: 0091 0674 2304 301, Fax No: 0091 674 2300728 18
- 19 E-mail: rkswain@ils.res.in
- 20 Dr. Ajay Parida (AP)
- 21 Plant and Microbial Biotechnology,
- 22 Institute of Life Sciences,
- 23 (Autonomous Institute of Dept of Biotechnology, Govt. of India),
- Nalco Square, Bhubaneswar-751023. Odisha, India 24
- 25 Phone No: 0091 674 2304324; Fax No: 0091 674 2300728
- 26 E-mail: drajayparida@gmail.com, ajayparida@ils.res.in
- 27 Dr. Satish Devadas (SD)
- NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. Infectious Disease Biology, 28

- 29 Institute of Life Sciences Institute of Life Sciences,
- 30 (Autonomous Institute of Dept of Biotechnology, Govt. of India),
- 31 Nalco Square, Bhubaneswar-751023. Odisha, India
- 32 Phone No: 0091 674 2300701; Fax No: 0091 674 2300728 E-mail: satdevs@ils.res.in

33 Abstract

Background: SARS-CoV2 infection in patients with comorbidities, particularly T2DM has been a major challenge globally. Here, we did whole blood immunophenotyping along with plasma cytokine, chemokine, antibody isotyping and viral load determination from oropharyngeal swab to understand the immune pathology in the T2DM patients infected with SARS-CoV2.

Methods: Blood samples from 25 Covid-19 positive patients having T2DM, 10 Covid-19 positive patients not having T2DM and 10 Covid-19 negative, non-diabetic healthy controls were assessed for various immune cells by analyzing for their signature surface proteins in mass cytometry. Circulating cytokines, chemokines and antibody isotypes were determined from plasma. Viral copy number was determined from oropharyngeal swabs. All our representative data corroborated with laboratory findings.

Results: Our observations encompass T2DM patients having elevated levels of both type I and
type II cytokines and higher levels of circulating IgA, IgM, IgG1 and IgG2 as compared to
NDM and healthy volunteers. They also displayed higher percentages of granulocytes, mDCs,
plasmablasts, Th2-like cells, CD4⁺ EM cells, CD8⁺ TE cells as compared to healthy volunteers.
T2DM patients also displayed lower percentages of pDCs, lymphocytes, CD8⁺ TE cells, CD4⁺,
CD8⁺ EM.

51 Conclusion: Our study demonstrated that patients with T2DM displayed higher inflammatory 52 markers and a dysregulated anti-viral and anti-inflammatory response when compared to NDM 53 and healthy controls.

54 **Contribution to the field:** Covid-19 infection in people with comorbidities, particularly 55 T2DM has been a cause of mortality in several nations and they represent an extremely 56 vulnerable population to Covid-19. This study is one of the most comprehensive study from 57 India, to understand the interplay between immune response and viremia occurring in these 58 T2DM patients infected with SARS-CoV2 and will help in designing public health response 59 and vaccination priorities.

Keywords- SARS-CoV2, Type II Diabetes, Whole blood Immunophenotyping, Innate
Immune Response, Adaptive Immune Response

63 Introduction

Since the outbreak of the novel coronavirus disease (Covid-19) in late 2019, India has 64 recorded over 34 million cases and 4,54,745 deaths as of 25th October, 2021 and now has the 65 second highest number of cases in the world, after the United States of America. Essentially, 66 SARS-Cov2 is a betacoronavirus, belonging to Coronaviridae family and is closely related to 67 68 SARS and MERS, which were responsible for earlier disease outbreaks in 2003 and 2011 69 respectively(1). Broadly, Covid-19 cases were and are still classified into symptomatic and asymptomatic, based on the presence or absence of symptoms and eventual severity based on 70 immune response and/or its failure. With respect to the symptoms of Covid-19 infection, 71 symptomatic patients have fever, dry cough, shortness of breath, acute respiratory distress, loss 72 of taste and smell and in certain cases diarrhoea (2, 3). Based on the intensity of these 73 symptoms, the patients are classified into mild and severe, during diagnosis. Prognosis of the 74 75 severe patients is critical. However, the major challenge arises from the huge population of asymptomatic cases, as they are responsible for the undetected spread of infection. 76

77 In general, disease severity in Covid-19 is associated with lymphopenia, cytokine storm, blood coagulation, drop in pO_2 levels, etc. (4, 5). However, with respect to the Indian 78 79 population, these clinical parameters and the associated immune response were not definitely present in most Covid-19 infected patients. Interestingly, one of the major attributes of Covid-80 81 19 in Indian population, especially in the first wave, was quick recovery, but the underlying immunological mechanism was and is yet to be understood. However, similar to the first wave, 82 83 70% of India's mortality in Covid-19 in the second wave is still attributed to comorbidities, specifically type II diabetes (T2DM). Although vaccinations drive initiated by the government 84 85 aims to protect the population in general, the overwhelming number of these patients poses a major challenge to recovery and recuperation of the individual. In that respect, co-relation 86 between comorbidities including T2DM and viral load, T2DM and glucose levels, etc. in the 87 patient can play a major role in dictating the immune response and eventual outcome of Covid-88 19 infection. Therefore, it is crucial to understand the interplay of these factors along with 89 immunological parameters to give us a comprehensive idea about the status of T2DM patients 90 having Covid-19. 91

92 Immune response can be divided into three types namely, type I (antiviral), type II (anti
93 helminthic), type III (antifungal). Type I response mainly constitutes of T-bet and Interferon
94 gamma (IFN-γ) mediated response, which is against intracellular pathogens, including viruses.

On the other hand, type II response is mediated by GATA-3 and is mainly against helminthic 95 worms, which are carried out by effector molecules such as IL-4, IL-9, and IgE. The third type 96 of response (type III response) is mediated by ROR-yt and effector molecules such as IL-17A, 97 IL-17F, 1L-22 etc. are responsible for controlling fungal infections (6, 7). Longitudinal 98 analysis has shown an immune dysregulation in Covid-19 patients and people with T2DM 99 contracting Covid-19 Infection had higher innate immune cells, lower T lymphocytes, a 100 sustained increase in antiviral, anti-fungal response and higher type 2 response such as IL-5, 101 102 IL-13, IgE and eosinophils (8).

103 Altogether, the immunological response in Covid-19 patients with co-morbidity is an 104 evolving area of study and these patients represents higher vulnerability in comparison to the 105 ones without any comorbidity or other comorbidities. Our study aims to elucidate the 106 differences between T2DM patients having Covid-19 as compared to those devoid of T2DM, 107 based on multiple parameters such as viral load, cytokine *milieu* and immune cells, which will 108 give us a comprehensive idea about the role played by T2DM in Covid-19 pathogenesis.

110 Materials and Methods

111 Population and Samples

A total of 25 samples with T2DM and 10 samples without T2DM (NDM) (Non-diabetes 112 mellitus) were collected. These samples were collected from hospital within 4 days of patient's 113 admission. Type II diabetes in these patients was confirmed by previous clinical history and 114 for this particular study was assessed by fasting plasma glucose level and glycated haemoglobin 115 and other clinical and biochemical parameters as requested by their consultant medical 116 practitioner. Amongst these, 22 patients with T2DM had hypertension. The T2DM or NDM 117 patients neither reported nor were assessed for other comorbidities during the infection. The 118 detailed laboratory findings are given in Table 1. All the T2DM patients had severe symptoms, 119 as assessed by the clinician. The NDM patients either had mild symptoms or were 120 asymptomatic. Additionally, 10 healthy volunteers who tested negative for Covid-19 were 121 included in the study to provide basal and or steady state biochemical and cytokine profile. 122 123 Briefly, 5ml blood was collected in BD Vacutainer EDTA tubes (BD 367863) and 270 µl of 124 whole blood from 10 T2DM patients, 5 NDM patients and 5 healthy volunteers was used for deep immune profiling by mass cytometry. The tubes were spun at 1600g for 20 minutes at 125 room temperature. Plasma was then collected and stored in -80 °C till further analysis. The 126 details of all the reagents and software used are given in the supplementary table 1 (S1). 127

128 SARS-CoV2 Viral load detection in respiratory specimen and plasma

300 µl each of oropharyngeal swab and plasma were taken for viral RNA extraction
using TAN Bead Maelstrom 4800 as per manufacturer's instructions. The extracted viral RNA
was stored at-80°C until further use (9).

132 **qRT-PCR**

The qRT-PCR was performed using 5µl of the extracted RNA from samples using the
TRUPCR SARS-CoV-2 RT qPCR Kit V-2.0. The human RNase P served as an internal control
whereas envelope (E) and nucleocapsid (N) genes were targeted for SARS-CoV-2
amplification (9).

137 Viral copy number determination

The viral copy number was determined for the above-mentioned samples by generating the standard curve of SARS CoV-2 N (nucleocapsid) gene. The N gene was cloned into pBiEx vector and 10-fold serial dilutions of the plasmid were done to obtain the standard curve. The

percentage of copy number/ml was calculated from the corresponding Ct values of all the
samples. For obtaining Ct values, cDNA was prepared from the extracted RNA using random
hexamers by TAKARA primescript 1st strand cDNA synthesis kit (Kusatsu, Japan). The
cDNA was subjected to qPCR (Mesagreen SYBR Green-No ROX, Eurogentec, Belgium)
using nucleocapsid gene specific primers. (FP: GTAACACAAGCTTTCGGCAG and RP:
GTGTGACTTCCATGCCAATG) (9).

147 Plasma Cytokine and Chemokine detection assay

Neat plasma from Covid-19 and controls was used to measure 41 cytokines and
chemokines using human Milliplex map cytokine assay kit (Millipore, Billerica, MA, USA).
The samples were acquired in a Bio-Plex 200 system (Bio-Rad, Hercules, CA, USA) and
cytokine concentrations were calculated using Bio-Plex manager software with a fiveparameter (5PL) curve-fitting algorithm applied for standard curve calculation (10).

153 Isotyping of circulating antibody from blood

For analysis of the isotype composition of antibodies in circulation, plasma of T2DM, 154 NDM patients and healthy volunteers, were analysed by ProcartaPlex Human Antibody 155 Isotyping Panels (Cat. No EPX070-10818-901, Invitrogen, Vienna, Austria), based on the 156 manufacturer's instructions. Briefly, antibody-coated magnetic bead mixtures were incubated 157 with 25µl of assay buffer, kit standards or diluted plasma (1:20000) samples in a ProcartaPlex 158 96-wells plate at room temperature for 1 hour. Detection antibodies (25 µl) were then added 159 and the plates were incubated on an orbital shaker at 500 rpm for 30 min. Next, the wells were 160 incubated with 50µl of diluted Streptavidin-Phycoerythrin for 30 min. Plates were then washed 161 using a hand-held magnetic plate washer. All incubations were performed at room temperature 162 in the dark. Afterwards, samples were suspended in 120 µl reading buffer. The samples were 163 acquired in a Bio-Plex 200 system (Bio-Rad, Hercules, CA, USA) and cytokine concentrations 164 were calculated using Bio-Plex manager software with a five-parameter curve-fitting algorithm 165 (5PL) applied for standard curve calculation (11). 166

167 Whole blood Immunophenotyping by Mass Cytometry

For immunophenotyping, 270µl of whole blood was collected, added to pre-coated
 Maxpar Direct Immune Profiling tubes and incubated for 30 minutes in room temperature. For
 lysis, 250µl of 1x BD FACs Lyse was added, followed by 10 min incubation. There were two
 consecutive washes with Maxpar water and Cell staining buffer. The cells were then fixed

with 4% formaldehyde and incubated for 10 minutes followed by washing at 800g for 5
minutes. Eventually, the cells were suspended in 1ml Iridium solution and stored in -80 °C till
acquisition. For acquisition, the cells were thawed, washed with Cell Staining buffer and Cell
Acquisition Solution. The cell density was adjusted to 1 million cells/ml in Cell acquisition
Solution with 0.1% EQ Beads and acquired in Helios Mass cytometer. FCS files were then
normalised with CyTOF software V.7 (Fluidigm) and then exported and analysed by FlowJo
software V10.7 (BD Biosciences)(12, 13).

179 Statistics

180 Statistical analysis was performed using the GraphPad Prism software, version 8.0.1. 181 Data was presented as Mean \pm Standard Deviation of Mean (SEM). Non-parametric Kruskal 182 Wallis Test with post hoc Dunn's multiple comparison test was used to compare the levels of 183 cytokines, antibodies and percentage of different immune cells among the three groups. Mann-184 Whitney U test was used to compare laboratory parameters between T2D and NDM patients. 185 *P* values less than 0.05 were considered significant (**P* < 0.05, ***P* < 0.01, ****P* < 0.001, 186 *****P* < 0.0001).

187 High dimensional analysis

For high dimensional analysis, t-SNE analysis was performed using FlowJo V.10.7 (BD 188 Biosciences). The gating for analysis was done on live, intact, CD45^{high}CD66b^{low} lymphocytes. 189 Amongst a total of 100,000 events, 5000 events in the lymphocyte population were used per 190 sample for this analysis. 5 samples of T2D and of Healthy controls were used to compute t-191 SNE and a total of 25000 events per group were concatenated and exported for t-SNE analysis. 192 The default parameters in the software, iterations-1000, perplexity-30, eta-675, KNN 193 algorithm-Exact (vantage point tree), gradient logarithm-Barnes-Hut were used to compute the 194 t-SNE plot. 195

196 Ethics Statement

197 The studies involving human participants were reviewed and approved by the 198 Institutional Human Ethics Committee, Institute of Life Sciences. The Institutional Ethics 199 Committee (IEC)/ Institutional Review Board (IRB) reference number is 106/HEC/2021. 200 Written consent informed to participate in this study was provided by the participants' 201 spouse/next of kin.

202 Data Availability Statement

203	The human	clinical	data	is	stored	at	KIMS	Hospital,	samples	are	stored	at	IL	S
-----	-----------	----------	------	----	--------	----	------	-----------	---------	-----	--------	----	----	---

Biorepository, Ethical clearance with the corresponding authors and on request for this, ethical,

legal, and privacy consent will be requested from both the doctor and patient to share data.

206 Author Contributions

- 207 Experimental Design and Conceptualization SD, SS and GB
- 208 Sample Collection and processing- RS, PP, SaS, SS, GB, SaC, PB and PN
- 209 Mass Cytometry Experiments- SS, GB and SKS
- 210 Chemokine and Cytokine Multiplexing- SS, SaC and GB
- 211 Antibody Isotyping- SS, SaC and AD
- 212 RT-PCR and Virological assays- SaC, AD and SC
- 213 Data analysis- SS, GB, SaC, AD, SC and SD
- 214 Manuscript Drafting- SS, GB, SaC, SC and SD
- 215 Manuscript Editing and Review- GB, SS, RS, PP, AP, SC and SD

216 **Conflict of Interest.**

The authors declare no conflict of interest. The funding agency had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

220 Funding.

This study was supported by the core funding of Institute of Life Sciences, Bhubaneswar, Dept of Biotechnology, India. SS was funded by the DBT fellowship. GB, SaC and SKS were funded by the CSIR fellowship.

224 Acknowledgements.

We would like to acknowledge ILS Biorepository for providing the SARS-CoV2 samples. We would like to thank Dr. Gajendra Motiram Jogdand for valuable suggestions in multiplexing. We would also like to thank Mr. Deepak Singh, Mr. Satyajit Behera and Ms. Jyotsna Priyadarshini for data entry.

229 **Results**

230 Viral load does not corroborate with inflammation in T2DM

The study was executed on NDM and T2DM Covid-19 patients, who had been detected 231 and admitted to a local tertiary COVID hospital. To examine for viral load, oropharyngeal 232 (OP) samples were collected from various patients as per established protocol and processed 233 in the BSL3 facility at ILS, Bhubaneswar. In most of the NDM and T2DM patients, there was 234 no significant difference in the viral copy number or $\Delta\Delta$ Ct values of OP samples at the time 235 236 of sampling (Fig. 1A and B). This suggests that the viral load in OP samples does not and did not correlate with disease severity in this population of study. This probably indicates that the 237 viral load present in the host does not dictate the severity of Covid-19 infection. 238

239 Altered cytokine and chemokine profiles in Covid-19 patients with Type II Diabetes

To investigate the status of systemic inflammation concurrent with SARS-Cov2 240 infection, we did multiplexing analysis of 41 cytokines and chemokines from the plasma of 241 T2DM and NDM patients to delineate the altered immune microenvironment in these patients. 242 243 For comparison and for basal level expression of these cytokines and chemokines, we added ten healthy volunteers and segregated the proteins into significant, moderate and mild based on 244 the level of their expression in T2DM as compared to NDM and healthy volunteers. 245 Accordingly, the levels of IL-6, TNF-a, G-CSF, GM-CSF, IFN-a2, IL-10, VEGF, IL-1Ra, IL-246 12p40, IL-15, IL-1 α , MIP-1 β , were found to be significantly elevated (p<0.0001, Kruskal 247 Wallis Test), indicating the simultaneous release of both Type I and Type II cytokines in 248 severity (Fig. 2A). In contrast, there was moderate elevation in the levels of IFN-y, EGF, IL-249 8, indicative of the ongoing antiviral reaction in these patients (Fig. 2B). Amongst the slightly 250 elevated ones, IP-10 (p=0.0365), IL-9, IL-4 (p=0.0146) showed higher significance (Fig. 2C). 251 Although IP-10 has been used as a real time marker for mortality in Covid-19 patients, we did 252 not do a longitudinal patient tracking, therefore cannot ascertain its role in mortality. In 253 addition, IL-4 and IL-9 which are both type II cytokines have also been linked to severity of 254 Covid-19 patients. Although our study could not find any significant difference in levels of 255 type III signature cytokines such as IL-17 and IL-1 β , the presence of type I and type II immune 256 signatures were overlapping in multiple patients (data not shown). However T2DM patients 257 showed elevation of both type I and type II cytokines indicating a dysregulated immune 258 response, prominent in these patients as earlier reported by Lucas et al (Fig. 2). 259

Interestingly, the levels of chemokines as opposed to cytokines, were higher in NDM 260 and healthy volunteers as opposed to T2DM patients. For example, the levels of Eotaxin were 261 found to be lower in T2DM than in NDM patients and healthy controls (Fig 2D). In general, 262 263 Eotaxin is associated with chemoattraction of eosinophils, basophils and neutrophils. Previous studies have reported its increase with severity but in our study, the population indicated a 264 265 reverse trend; decreasing Eotaxin levels in the T2DM patients. This can be indicative of an impaired healing process as previous reports have suggested a positive correlation between 266 267 increasing number of eosinophils and healing. In addition, sCD40L was elevated in NDM patients as compared to T2DM and healthy volunteers (Fig. 2E). Since sCD40L has been 268 associated with immunosuppression, it is indicative of an anti-inflammatory immune response 269 in NDM patients, which is clearly absent in T2DM cases. Similarly, the levels of MDC 270 (macrophage derived chemokine) were also higher in NDM as compared to T2DM patients, 271 demonstrating its potential role in immune suppression (Fig. 2E). In addition, GRO levels 272 were higher in both NDM and T2DM patients as compared to healthy controls (Fig. 2F). As 273 GRO serves as a chemoattractant for neutrophils, it is indirectly indicative of the status of 274 underlying inflammation in NDM and T2DM patients. Collectively, our cytokine and 275 chemokine profile of T2DM patients showed an increasing trend in the inflammatory cytokine 276 panel and augmented levels of chemokines that were primarily responsible for repair and 277 278 angiogenesis.

279 Circulating antibody isotype profiling showed a skewed inflammatory profile in Covid-19 280 patients with Type II Diabetes

Various antibody isotypes correlate with the clinical phenotype of an infection and is 281 282 therefore an important indicator of the type of immune response. Since cytokine *milieu* in T2DM and NDM patients was skewed, we wanted to define the circulating antibody isotypes 283 in these patients as opposed to healthy controls. We did Luminex based multi plex assay from 284 their plasma and quantified the amount of IgA, IgM, IgE, IgG1, IgG2, IgG3 and IgG4. Here, 285 we found IgG1 and IgG2 to be significantly elevated in T2DM patients as compared to healthy 286 controls (p=<0.0001) and NDM patients (p=0.0024 for IgG1 and p=0.0033 for IgG2), 287 correlating with the higher levels of type I cytokines in these patients. IgE, being a hallmark 288 of type II immune response was also elevated in T2DM as compared to NDM (p=0.0453) and 289 healthy control (p=0.0347). Alongside, IgA being associated with mucosal immunity was also 290 higher in T2DM patients as compared to NDM (p=0.0012) and healthy controls (p=0.0140). 291 As IgM is the first antibody isotype to appear during the course of infection, accordingly we 292

found its levels to be higher in T2DM patients as compared to NDM (p=0.0178) and healthy controls (p=0.0017) (Fig. 3). In summary, the antibody isotype profile was concurrent to the cytokine levels, thus confirming and furthering the status of disease severity in Covid-19 patients.

297 Dysregulated innate immune system in Covid-19 patients with Type II Diabetes

With the cytokine multiplexing and antibody isotyping indicating an altered immune 298 response, our next objective was to delineate the alteration in the cells of innate and adaptive 299 immune system during Covid-19. Based on the surface markers analysed, we found T2DM 300 patients showing significant increase in CD45lowCD66bhigh granulocytes as compared to 301 healthy controls (p=0.0074), which is concurrent with the increase in the levels of IL-8 (Fig. 302 **4A**). The bulk population of these granulocytes were neutrophils, though we did not find any 303 significant difference between the levels of neutrophils in T2DM, NDM and healthy controls 304 (data not shown). Also, dendritic cell populations were variable, with their numbers decreasing 305 306 in T2DM as compared to NDM and healthy controls (Fig. 4B). This was in contrast to the increase in IFN- α 2 levels, indicating towards dysregulated dendritic cell population in T2DM 307 patients (Fig. 2A). Within the dendritic cell population, plasmacytoid dendritic cells (pDCs) 308 decreased in T2DM patients as compared to NDM and healthy controls (Fig. 4B). However, 309 percentage of myeloid dendritic cells (mDCs) increased in T2DM patients as compared to 310 NDM and healthy controls (Fig. 4C). The percentage of basophils was also reduced in T2DM 311 patients as compared to healthy volunteers, which was correlating with the decrease in levels 312 of chemokine, Eotaxin (CCL11) (Fig. 4D). Although, we did not observe any variation 313 between T2DM, NDM and healthy controls in the populations of gamma delta cells and natural 314 killer cells there was reduction in the percentage of MAIT/NKT cells in T2DM patients as 315 316 compared to healthy and NDM patients (Fig. 4E). As reported earlier (data not shown), there were no changes in the overall or subsets of monocytes and natural killer cells. Altogether, 317 318 alterations in the innate immune cell population is suggestive of an aberrant immune response incapable of controlling the infection. 319

Heterogenicity in Lymphocyte population in Covid-19 patients with Type II Diabetes, NDM and healthy controls

Lymphocytes are instrumental in fighting infections and earlier reports indicated towards its decreasing trend in T2DM patients. There was a moderate decrease in the percentage of lymphocyte in T2DM as compared as to the healthy controls (Fig. 4A). Amongst

lymphocytes, percentage of total B cell population was expanding in T2DM patients as 325 compared to healthy controls (Fig. 5A) and was is in direct correlation with increased IgG1 326 and IgG2 in the former (Fig. 3). Further analyses revealed a significant increase in plasmablast 327 population in T2DM patients as compared to healthy controls. Additionally, we found a 328 significant decrease in the percentage of CD3⁺ T cells in T2DM patients as compared to healthy 329 controls suggesting lymphopenia associated with increased severity (Fig. 5B). Within the T 330 cell population, there was an increase in the percentage CD4⁺ T cells (statistically insignificant) 331 but decrease of CD8⁺ T cells (Fig. 5B). Further, in depth analysis of CD4⁺ T cells revealed 332 that T2DM patients had an increase of the Th2 subtype as compared to NDM or healthy 333 volunteers (Fig. 5C). This can be correlated with the increased levels of IL-4 and IL-9, found 334 in the plasma of these patients (Fig. 2C). However, Th1, Th17, Treg and Tfh cells did not 335 show any statistically significant difference, which can be attributed to the time of sampling or 336 be a consequence of dysregulated immune response. There was also no significant difference 337 in Naïve CD4⁺ T cells or Central memory CD4⁺ T cells within the groups. But terminal effector 338 (TE) cells were decreased and effector memory (EM) cells were increased in T2DM patients 339 as compared to healthy controls (Fig. 5D). This was in contrast to the CD8⁺ compartment, 340 where TE cells were increased in T2DM patients as compared to NDM but there was no 341 difference between T2DM and healthy controls suggesting a robust response in NDM patients 342 343 as compared to T2DM and a certain degree of cross-reactive reaction occurring in these T2DM patients (Fig. 5E). Similarly, there was significant decrease of EM cells in T2DM as compared 344 to NDM while no difference was observed in healthy controls when compared to T2DM or 345 NDM. Collectively, a bias was found towards terminal effector CD8⁺ T cells in T cell immune 346 response which was suggestive of an effective ongoing anti-viral response. 347

High Dimensional analysis reveals immune perturbations in T2DM patients 348

We also performed t-distribution stochastic neighbour embedding (t-SNE) analysis to 349 understand how different markers reported previously, show variability in Covid-19 patients 350 in our population of study. t-SNE analysis revealed a decrease in the expression of CD3 and 351 CD8 in T2DM patients as compared to healthy volunteers (Fig. 6A). On the contrary, there 352 was increase in the expression of CD14, CD38 and HLA-DR in T2DM patients as compared 353 to healthy volunteers (Fig. 6B). 354

355 **Discussion**

The Covid-19 pandemic has brought an unprecedented global devastation on lives and 356 livelihood of the common people, breakdown of the best healthcare system and economic 357 collapse all across the globe. Till October 2021, India reported around 34 million cases, being 358 359 second in place to the United States of America. Unfortunately, a bulk population of Covid-19 cases in India who had succumbed to the infection had comorbidities and amongst these, 360 Type II Diabetes was the most common. At present, there are no significant reports from India 361 providing an insight into the variations in immune response, extent of inflammation and 362 outcome in T2DM patients as compared to NDM patients and healthy volunteers. In this study, 363 we attempted to describe and compare immune response, viral loads and clinical parameters 364 amongst T2DM, NDM and healthy volunteers. In that respect, 25 patients with T2DM, 10 365 NDM patients and 10 healthy volunteers were studied for cytokine, chemokine, viral loads, 366 clinical parameters and antibody isotyping assays for understanding the immunopathology of 367 the virus. Ten T2DM, five NDM and five healthy volunteers were studied for whole blood 368 369 mass cytometry assay to determine the difference in immune cells amongst the groups. While it is understood that this is a very small group, some clear patterns are established here 370 suggesting that the chronic Meta inflammation in Type II Diabetes might play a role in further 371 precipitating the inflammatory signatures in Covid-19. 372

It is known that mild inflammation serves as one of the major initiator mechanisms of 373 the immune system that is extremely crucial in fighting infection (14). However elevated levels 374 of circulatory cytokines and eventual cytokine storm and dysregulated inflammatory responses 375 have been evinced in Covid-19 infection (2, 4). Additionally, previous reports suggest that 376 patients with T2DM have a higher vulnerability for SARS-CoV2 infection (15, 16) where 377 persistent low grade inflammation associated with T2DM was evinced but not co related to be 378 causal. Our data taken together with biochemical, cytokine and antibody profile strongly 379 indicate that chronic low grade inflammation and the consequential dysregulated immune 380 response might be responsible for the upsurge of inflammatory responses in Covid-19 patients 381 leading to severe infection and or mortality. 382

Our preliminary objective in the study was to assess the differences in viremia in Oropharyngeal swab between the two groups. However, viral load of OP samples did not show any significant difference between the two groups. This was in accordance with previous studies, where it was observed that the viral load in nasal and throat swab samples were similar

in the NDM and T2DM patients (17, 18). Here, the T2DM are considered as severe Covid-19
patients, based on the severity of their symptoms. And, the NDM patients either had NDM
symptoms (n=4) or were asymptomatic (n=6). This is evident from the clinical parameters as
T2DM patients had higher levels of CRP which is a non-specific inflammatory marker,
dysregulated glucose metabolism as evident from higher plasma glucose, glycated
haemoglobin and impaired blood coagulation as interpreted from higher d-dimer levels(19-22).

Cytokines and chemokines are soluble mediators that control the migration of immune 393 cells to the site of inflammation, providing a pro or anti-inflammatory environment which 394 essentially shapes the type of immune response during a disease. In our T2DM patients who 395 were infected with SARS-CoV2, higher expression of both type I and type II cytokines were 396 evinced. Previous reports suggest the involvement of both the types of cytokines in aggravating 397 the severity of the disease. Increase in type I cytokines such as IFN- γ TNF- α , IFN- α 2, IL-6, 398 GMCSF, IL-8 indicated a robust antiviral and inflammatory response occurring in these T2DM 399 patients. Additionally, these patients also showed an increase in type II cytokines such as IL-4 400 and IL-9, representing the anti-inflammatory response. Here, we understand that the presence 401 of both inflammatory and anti-inflammatory cytokines in T2DM patients as indicators of a 402 dysregulated immune response where the anti-inflammatory response was clearly incapable of 403 404 shutting the cytokine storm in these patients(23).

In diabetic patients, there is an increase in the inflammatory cytokines, CRP levels and 405 the presence of blood clots. As similar symptoms are associated with Covid-19 i.e. elevated 406 CRP levels, D-dimer and inflammatory cytokines, this suggests towards a synergistic effect 407 found in T2DM patients infected with SARS-Cov2, which was reduced in NDM patients. 408 Additionally, our study suggested an increase in IL-15 and 1L-7 in T2DM patients when 409 compared to NDM and healthy volunteers. As it is known that IL-15 is crucial for promoting 410 411 cytotoxic activity of both, NK and CD8⁺ T cells and is also involved in memory CD8⁺ T cell differentiation, it should have led to increase in the CD8⁺ population(24). However, we found 412 a decrease in the CD8⁺ cell population, specifically in the EM compartment, again indicating 413 a dysregulated or non-responsive immune response in these patients. This might be a 414 consequence of reduced receptors for IL-15 in these cells. As IL-7 is also required for T cell 415 development and maintenance(25), its increased numbers in T2DM patients partially 416 corroborated with the increase in CD8⁺ TE cells and CD4⁺ EM cells. However, as a 417 consequence of immune dysregulation, neither the elevated levels of the above mentioned 418 cytokines nor the CD8⁺ T cells, are capable of controlling the inflammation. 419

The sCD40L is one of the major co-stimulatory molecules on activated T cells that 420 interact with CD40 on B cells and is responsible for immunoglobulin isotype switching in the 421 membrane-bound form(26). In our study, levels of sCD40L were elevated in NDM as 422 compared to the T2DM patients indicating that the NDM patients may be undergoing an 423 immuno suppressive reaction, as elevated sCD40L is also associated to immunosuppression. 424 GRO (CXCL1) is a chemokine that attracts variety of immune cells, particularly neutrophils 425 and is also implicated in wound healing process(27). Similar to sCD40L levels, GRO levels 426 427 were also higher in NDM as compared to T2DM patients indicating that both inflammation and healing were occurring simultaneously in these patients. However, the healing mechanism 428 was definitely poorer in T2DM patients. The levels of Macrophage-derived chemokine 429 (MDC/CCL2) were also higher in NDM patients than T2DM patients. As MDC is known to 430 be elevated in lung inflammation and hemorrhage but reduced in T2DM symptomatic patients, 431 this is also suggesting towards a possible immunosuppressive function of MDC in this 432 population(28). 433

To understand how different antibody isotypes influence the clinical phenotype in 434 435 T2DM and NDM patients, we did an antibody isotyping from the plasma of these patients. Here, we found significant difference in the levels of IgA, IgM, IgG1, IgG2 and IgE between 436 the two groups but IgG3 and IgG4 did not show any significant difference and we understand 437 that the structure and function of different antibody isotypes vary from one another. For 438 example, IgG1, IgG2 and IgG3 can fix complement(29). However, IgG4 cannot fix 439 complement and is unable to induce antibody mediated cell cytotoxicity (ADCC). Similar to 440 previous reports, we found an increase in the levels of IgE in T2DM patients(8, 16). This 441 corroborated with the increase in the Th2 subset along with increase in cytokines, IL-4 and IL-442 9 in T2DM patients, as it is known that IgE is associated with Type II response. In addition, 443 there was also an increase in IgG1 and IgG2 in these patients, indicative of the inflammatory 444 response. However, as IgE was high in these T2DM patients, we could see no significant 445 difference in IgG4 levels. This could be accredited to the competition between IgE and IgG4 446 against each other, for fixation sites in basophils and mast cells, as suggested by previous 447 reports(30). IgA levels were also found to be higher in T2DM, indicating towards viral immune 448 response at mucosal surfaces(31). With respect to IgM, its increased levels indicate towards 449 an ongoing infection. However, the lack of any longitudinal profiling restricts us from 450 understanding its specificity to antigen(32). 451

With respect to our whole blood analysis by mass cytometry, we found an increase in 452 453 the percentage of granulocytes in T2DM patients when compared to healthy controls indicating underlying inflammatory responses in these patients. This is consistent with other reports 454 which suggested an increase in granulocytes with increasing severity(15, 33). On the other 455 hand, we found a decreasing percentage of monocytes in T2DM patients as compared to NDM 456 patients (Table 1), although the difference was not significant. This has also been reported in 457 a previous study showing the absence of any significant changes in the total monocytes and its 458 subsets in T2DM patients with various comorbidities, T2DM being one of them(15). 459 Additionally, we also found that T2DM patients showed a decreasing trend in lymphocyte 460 percentage as compared to NDM and healthy volunteers, as reported in previous studies (4, 8, 461 15). One of the significant findings from our study is that, there is a drastic reduction in the 462 percentage of total dendritic cells in T2DM patients when compared to both, NDM and healthy 463 controls. Within the dendritic cell compartments, there is a decrease of pDCs but mDCs have 464 increased in T2DM patients when compared with healthy controls. In general, pDCs are known 465 to secrete type I interferons in response to viral infection(34). However, our study has shown 466 a decrease in the percentage of pDCs, but increase in the cytokine IFN- α 2. This is suggesting 467 that although these cells are secreting high levels of type I interferon, their numbers are depleted 468 in T2DM patients and thus, are unable to control the infection. With respect to mDCs, they are 469 known to secrete the cytokines IL-12 and TNF- α , which polarizes the T cell towards a type I 470 response, crucial for controlling the viruses(35, 36). Our study also observed an increase in 471 the population of mDCs along with increase in the cytokines, IL-12p40, TNF- α in T2DM. 472 Although certain reports have suggested a decrease of mDCs along with pDCs, we observed 473 the presence of high numbers of mDCs in diabetic patients, indicating an ongoing low grade 474 475 inflammation, which is further augmented with Covid-19 infection. However, since we did not do a longitudinal profiling, we could not delineate the mDC dynamics in these patients(37, 476 38). 477

With respect to basophils, literature suggested a decrease in its population with 478 increasing severity(39). We found a similar trend, as the basophil population decreased in 479 T2DM patients as compared to healthy controls. Similarly, MAIT/iNKT cells were 480 significantly decreased in T2DM patients as compared to NDM and healthy controls. 481 However, no significant differences were observed in the percentage of gamma delta T cells. 482 A decrease in MAIT/iNKT could indicate towards a migration to other inflamed tissues 483 including the lungs, as suggested by the previous reports. With respect to NK cell population, 484

it is known that they play a crucial role in fighting viral infections and previous reports
suggested a decrease in their numbers in T2DM cases. However, our population of study did
not show any significant difference amongst the groups and as mentioned earlier may be a
consequence of the time of sampling of patients(40, 41).

In case of B cells, we observed a slight elevation in its percentage in T2DM patients, 489 490 when compared to NDM and healthy controls, but statistical difference was found only between T2DM patients and healthy volunteers. Although no difference was observed in naive 491 or memory B cell compartment, plasmablasts were significantly elevated in T2DM patients as 492 compared to healthy controls. The increase in plasmablasts in T2DM Covid-19 has also been 493 reported in other studies (8, 15)but unlike our study, they could not correlate it with any 494 comorbidity. Interestingly, there are reports suggesting an increase in extrafollicular B cell 495 response in Covid-19 and other inflammatory diseases such as Systemic Lupus Erythematous. 496 Since most of the Covid-19 patients had type II diabetes in our study, we hypothesize that these 497 two factors might have augmented the plasmablast production. Although we did not analyze 498 the clonality of B cells, but earlier study has suggested an oligoclonal expansion of B cells in 499 500 T2DM Covid-19, in turn correlating with increased plasmablast production. Increased B cell population in T2DM patients also corroborated with the fact that most of the immunoglobulins 501 (IgM, IgA, IgG and IgE) were elevated in these patients as opposed to NDM and healthy 502 volunteers. Altogether, we found an increase in the plasmablast population in T2DM as 503 compared to NDM patients and healthy volunteers, suggesting that the low grade inflammation 504 in Diabetic patients resulted in increase in plasmablast population, which augmented further 505 with Covid-19 infection in these patients. 506

507 T2DM patients also displayed a lower percentage of CD45⁺CD3⁺ T cells as compared to healthy controls. Within CD3⁺ T cell population, there was a decrease in the percentage of 508 CD8⁺ T cells in T2DM as compared to healthy volunteers. However, CD4⁺ T cells did not 509 show any statistically significant difference amongst the groups. Earlier reports have suggested 510 the loss of CD8⁺ T cells being greater than CD4⁺ T cells. Since our population of study was 511 small with heterogenous manifestation, this could explain why CD4⁺ T cells did not show any 512 difference amongst the groups. Additionally, several reports indicate towards T cell apoptosis 513 or migration to other tissues in SAR-CoV2 infection, leading to decrease in T cell population 514 in the periphery and could account for the decrease in T cells in the T2DM patients(42-44). In 515 general, there was decrease in the CD3⁺ T cell population, where the CD8⁺ compartment was 516 affected more significantly than CD4⁺. 517

Type II diabetes has been reported to have various aberrancies such as an impaired 518 differential potential and secretion of multiple proinflammatory cytokines such as TNF-a and 519 520 IFN- $\gamma(37, 45)$. Although we could not find any significant difference amongst the groups in the percentage of Th1 like, Th17 like, Treg or cTfh subtypes, there was an increase in the 521 proinflammatory cytokines. We understand that the absence of difference amongst the groups 522 with respect to T cell subsets can be accounted to the time of sampling. On the other hand, our 523 study found an increase in the percentage of Th2 cells secreting type II cytokines such as IL-4 524 and IL-9. The high numbers of Th2 cells partially explained the augmented levels of 525 immunoglobulins in these patients, specifically IgE which is induced by cytokines such as IL-526 4. Taken together, this indicated that the Diabetic patients already had low grade inflammation. 527 When encountered with Covid-19, dysregulation in the immune system escalated to such levels 528 that even with the increase in Th2 population secreting anti-inflammatory cytokines, 529 inflammation could not subdue. 530

We also analyzed for the naïve, effector and memory compartments in both CD4⁺ and 531 CD8⁺ T cells. In CD4⁺ T cells, we did not see any difference in the overall percentage of naive 532 (CCR7⁺CD45RA⁺CD45RO⁻) and central memory cells (CCR7⁺CD45RA⁻CD45RO⁺) amongst 533 the various groups. However, effector memory cells (CCR7⁻CD45RA⁻CD45RO⁺CD27⁺) were 534 elevated in T2DM patients when compared to healthy controls, suggesting cross reactivity with 535 other family of coronavirus, as reported by a previous study from India(46, 47). An important 536 point to note here is that central memory cells did not show any significant difference and this 537 may be due to the fact that CM cells are lymph node residents as opposed to EM cells, which 538 circulate in blood and thus, respond faster to the antigen (data not shown). However, since we 539 did not analyze for the antigen specific cells, therefore we were unable to find any significant 540 difference in the percentage of CM cells. Terminal effector (CCR7⁻CD45RA⁻CD45RO⁺CD27⁻ 541) cells were decreased in T2DM patients with Covid-19 as compared to healthy controls, 542 corroborating with the observation that these cells are first to react with the virus and the 543 subsequent proinflammatory cytokine milieu is responsible for the apoptosis of these cells. 544

In CD8⁺ T cell compartment, EM (CCR7⁻CD27⁺) cells were elevated in NDM as compared to T2DM patients, indicating an effective immune response in these patients but less effective in T2DM patients. TE (CCR7⁻CD27⁻) cells increased in T2DM patients indicating that these cells are highly inflammatory and might be insensitive to AICD (47-49).

Altogether, our data suggests that Meta inflammation present in these T2DM patients 549 550 is responsible for aggravation of the inflammation occurring due to Covid-19. With T2DM being one of the most common morbidity presents in India, these patients remain most 551 vulnerable and were susceptible to secondary infections like mucormycosis. Though 552 vaccinations are lowering the severity of the disease, reported waning antibody response in 3-553 554 6 months is a major concern apart from how long the protective immunity from T cells will work in these patients is also yet to be ascertained. Our study is essentially aimed at 555 556 understanding how a low grade chronic inflammatory disorder such as Type II Diabetes dictates the immune response during the pathogenesis of Covid-19. We understand that our 557 study is not devoid of limitations such as a small sample size, absence of longitudinal study or 558 follow up, but nevertheless it will help in understanding the vulnerability of these patients and 559 subsequent planning of vaccine coverage in these patients or future vaccines booster dosages 560 to them. 561

References 562

563

564 1. Chen Y, Liu Q, Guo D. Emerging coronaviruses: Genome structure, replication, and 565 pathogenesis. J Med Virol. 2020;92(10):2249.

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 566 2. 567 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506.

Berlin DA, Gulick RM, Martinez FJ. Severe Covid-19. N Engl J Med. 2020;383(25):2451-60. 568 3.

Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of Immune Response in Patients 569 4. 570 With Coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis. 2020;71(15):762-8.

Iba T, Levy JH, Levi M, Thachil J. Coagulopathy in COVID-19. J Thromb Haemost. 571 5. 572 2020;18(9):2103-9.

573 Annunziato F, Romagnani C, Romagnani S. The 3 major types of innate and adaptive cell-6. 574 mediated effector immunity. J Allergy Clin Immunol. 2015;135(3):626-35.

O'Shea JJ, Paul WE. Mechanisms underlying lineage commitment and plasticity of helper CD4+ 575 7. 576 T cells. Science. 2010;327(5969):1098-102.

577 Lucas C, Wong P, Klein J, Castro TBR, Silva J, Sundaram M, et al. Longitudinal analyses reveal 8. immunological misfiring in severe COVID-19. Nature. 2020;584(7821):463-9. 578

579 9. Chatterjee S, Datey A, Sengupta S, Ghosh A, Jha A, Walia S, et al. 2021.

580 Jogdand GM, Sengupta S, Bhattacharya G, Singh SK, Barik PK, Devadas S. Inducible 10. Costimulator Expressing T Cells Promote Parasitic Growth During Blood Stage Plasmodium berghei 581 ANKA Infection. Front Immunol. 2018;9:1041. 582

11. Prodjinotho UF, von Horn C, Debrah AY, Batsa Debrah L, Albers A, Layland LE, et al. 583 584 Pathological manifestations in lymphatic filariasis correlate with lack of inhibitory properties of IgG4 585 antibodies on IgE-activated granulocytes. PLoS Negl Trop Dis. 2017;11(7):e0005777.

Bagwell CB, Hunsberger B, Hill B, Herbert D, Bray C, Selvanantham T, et al. Multi-site 586 12. 587 reproducibility of a human immunophenotyping assay in whole blood and peripheral blood mononuclear cells preparations using CyTOF technology coupled with Maxpar Pathsetter, an 588 589 automated data analysis system. Cytometry B Clin Cytom. 2020;98(2):146-60.

medRxiv preprint doi: https://doi.org/10.1101/2021.12.03.21267282; this version posted December 26, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

590 13. Geanon D, Lee B, Gonzalez-Kozlova E, Kelly G, Handler D, Upadhyaya B, et al. A streamlined
591 whole blood CyTOF workflow defines a circulating immune cell signature of COVID-19. Cytometry A.
592 2021;99(5):446-61.

59314.Tay MZ, Poh CM, Renia L, MacAry PA, Ng LFP. The trinity of COVID-19: immunity, inflammation594and intervention. Nat Rev Immunol. 2020;20(6):363-74.

595 15. Kuri-Cervantes L, Pampena MB, Meng W, Rosenfeld AM, Ittner CAG, Weisman AR, et al.
596 Comprehensive mapping of immune perturbations associated with severe COVID-19. Sci Immunol.
597 2020;5(49).

598 16. Zhao R, Sun Y, Zhang Y, Wang W, Wang S, Wang C, et al. Distinguishable Immunologic
599 Characteristics of COVID-19 Patients with Comorbid Type 2 Diabetes Compared with Nondiabetic
600 Individuals. Mediators Inflamm. 2020;2020:6914878.

Sohn Y, Jeong SJ, Chung WS, Hyun JH, Baek YJ, Cho Y, et al. Assessing Viral Shedding and
Infectivity of Asymptomatic or Mildly Symptomatic Patients with COVID-19 in a Later Phase. J Clin
Med. 2020;9(9).

18. Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, et al. SARS-CoV-2 Viral Load in Upper
Respiratory Specimens of Infected Patients. N Engl J Med. 2020;382(12):1177-9.

Li G, Chen Z, Lv Z, Li H, Chang D, Lu J. Diabetes Mellitus and COVID-19: Associations and
Possible Mechanisms. Int J Endocrinol. 2021;2021:7394378.

608 20. Chen L, Deng H, Cui H, Fang J, Zuo Z, Deng J, et al. Inflammatory responses and inflammation-609 associated diseases in organs. Oncotarget. 2018;9(6):7204-18.

Yaribeygi H, Sathyapalan T, Jamialahmadi T, Sahebkar A. The Impact of Diabetes Mellitus in
COVID-19: A Mechanistic Review of Molecular Interactions. J Diabetes Res. 2020;2020:5436832.

612 22. Guo W, Li M, Dong Y, Zhou H, Zhang Z, Tian C, et al. Diabetes is a risk factor for the progression 613 and prognosis of COVID-19. Diabetes Metab Res Rev. 2020:e3319.

614 23. Ozsurekci Y, Aykac K, Er AG, Halacli B, Arasli M, Oygar PD, et al. Predictive value of 615 cytokine/chemokine responses for the disease severity and management in children and adult cases 616 with COVID-19. J Med Virol. 2021;93(5):2828-37.

617 24. Verbist KC, Klonowski KD. Functions of IL-15 in anti-viral immunity: multiplicity and variety.
618 Cytokine. 2012;59(3):467-78.

Tani-ichi S, Shimba A, Wagatsuma K, Miyachi H, Kitano S, Imai K, et al. Interleukin-7 receptor
controls development and maturation of late stages of thymocyte subpopulations. Proc Natl Acad Sci
U S A. 2013;110(2):612-7.

Huang J, Jochems C, Talaie T, Anderson A, Jales A, Tsang KY, et al. Elevated serum soluble CD40
ligand in cancer patients may play an immunosuppressive role. Blood. 2012;120(15):3030-8.

27. Zaja-Milatovic S, Richmond A. CXC chemokines and their receptors: a case for a significant
biological role in cutaneous wound healing. Histol Histopathol. 2008;23(11):1399-407.

828. Richter JR, Sutton JM, Belizaire RM, Friend LA, Schuster RM, Johannigman TA, et al.
Macrophage-derived chemokine (CCL22) is a novel mediator of lung inflammation following
hemorrhage and resuscitation. Shock. 2014;42(6):525-31.

429 29. van der Zee JS, van Swieten P, Aalberse RC. Inhibition of complement activation by IgG4
antibodies. Clin Exp Immunol. 1986;64(2):415-22.

30. Dodev TS, Bowen H, Shamji MH, Bax HJ, Beavil AJ, McDonnell JM, et al. Inhibition of allergendependent IgE activity by antibodies of the same specificity but different class. Allergy.
2015;70(6):720-4.

63431.Sterlin D, Mathian A, Miyara M, Mohr A, Anna F, Claer L, et al. IgA dominates the early635neutralizing antibody response to SARS-CoV-2. Sci Transl Med. 2021;13(577).

32. Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, et al. Antibody Responses to SARS-CoV-2 in
Patients With Novel Coronavirus Disease 2019. Clin Infect Dis. 2020;71(16):2027-34.

638 33. Vitte J, Diallo AB, Boumaza A, Lopez A, Michel M, Allardet-Servent J, et al. A Granulocytic
639 Signature Identifies COVID-19 and Its Severity. J Infect Dis. 2020;222(12):1985-96.

medRxiv preprint doi: https://doi.org/10.1101/2021.12.03.21267282; this version posted December 26, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

640 34. Cervantes-Barragan L, Zust R, Weber F, Spiegel M, Lang KS, Akira S, et al. Control of
641 coronavirus infection through plasmacytoid dendritic-cell-derived type I interferon. Blood.
642 2007;109(3):1131-7.

st. van der Molen RG, Sprengers D, Binda RS, de Jong EC, Niesters HG, Kusters JG, et al. Functional
impairment of myeloid and plasmacytoid dendritic cells of patients with chronic hepatitis B.
Hepatology. 2004;40(3):738-46.

646 36. Cella M, Salio M, Sakakibara Y, Langen H, Julkunen I, Lanzavecchia A. Maturation, activation,
647 and protection of dendritic cells induced by double-stranded RNA. J Exp Med. 1999;189(5):821-9.

37. Yao K, Lu H, Huang R, Zhang S, Hong X, Shi H, et al. Changes of dendritic cells and fractalkine
in type 2 diabetic patients with unstable angina pectoris: a preliminary report. Cardiovasc Diabetol.
2011;10:50.

- 38. Sun Y, Zhou J, Ye K. White Blood Cells and Severe COVID-19: A Mendelian Randomization
 Study. J Pers Med. 2021;11(3).
- 65339.Jouan Y, Guillon A, Gonzalez L, Perez Y, Boisseau C, Ehrmann S, et al. Phenotypical and654functional alteration of unconventional T cells in severe COVID-19 patients. J Exp Med. 2020;217(12).
- 40. Parrot T, Gorin JB, Ponzetta A, Maleki KT, Kammann T, Emgard J, et al. MAIT cell activation and dynamics associated with COVID-19 disease severity. Sci Immunol. 2020;5(51).
- 41. Zhai X, Qian G, Wang Y, Chen X, Lu J, Zhang Y, et al. Elevated B Cell Activation is Associated with Type 2 Diabetes Development in Obese Subjects. Cell Physiol Biochem. 2016;38(3):1257-66.
- 42. Shrotri M, van Schalkwyk MCI, Post N, Eddy D, Huntley C, Leeman D, et al. T cell response to SARS-CoV-2 infection in humans: A systematic review. PLoS One. 2021;16(1):e0245532.
- 43. Mazzoni A, Salvati L, Maggi L, Capone M, Vanni A, Spinicci M, et al. Impaired immune cell
 cytotoxicity in severe COVID-19 is IL-6 dependent. J Clin Invest. 2020;130(9):4694-703.
- 663 44. Gil-Etayo FJ, Suarez-Fernandez P, Cabrera-Marante O, Arroyo D, Garcinuno S, Naranjo L, et al.
 664 T-Helper Cell Subset Response Is a Determining Factor in COVID-19 Progression. Front Cell Infect
 665 Microbiol. 2021;11:624483.
- Ansari A, Arya R, Sachan S, Jha SN, Kalia A, Lall A, et al. Immune Memory in Mild COVID-19
 Patients and Unexposed Donors Reveals Persistent T Cell Responses After SARS-CoV-2 Infection. Front
 Immunol. 2021;12:636768.
- 46. Lipsitch M, Grad YH, Sette A, Crotty S. Cross-reactive memory T cells and herd immunity to
 SARS-CoV-2. Nat Rev Immunol. 2020;20(11):709-13.
- 47. Harty JT, Tvinnereim AR, White DW. CD8+ T cell effector mechanisms in resistance to infection. Annu Rev Immunol. 2000;18:275-308.
- 48. Reiser J, Banerjee A. Effector, Memory, and Dysfunctional CD8(+) T Cell Fates in the Antitumor
 Immune Response. J Immunol Res. 2016;2016:8941260.
- 49. Martin MD, Badovinac VP. Defining Memory CD8 T Cell. Front Immunol. 2018;9:2692.
- 676
- 677
- 678
- 679




Fig 1. Analysis of Viral load in Oropharyngeal samples in Covid-19 patients.(A) Bar diagram depicting the viral copy number of Oropharyngeal (OP) samples collected from T2DM(n=25) and NDM(n=10) COVID-19 patients.(B) Bar diagram representing the $\Delta\Delta$ CT of OP samples of NDM and T2DM COVID-19 patients. The Mann-Whitney (non parametric, two tailed) test was performed. ns, not significant. All error bars were SEM.




Fig 2.Analysis of the cytokines and chemokines in T2DM ,NDM patients infected with SARS-CoV2

Fig 2. Analysis of the cytokines and chemokines in 12D4 patients intercel with SARS-C042 The bar diagrams representing cytokines and chemokines which were evaluated from COVID -19 positive plasma samples of T2DM(n=25), NDM(n=10) and Covid-19 negative and non-diabetic healthy controls(n=10).(A)IL-6.TNF- α ,GCSF,IL-12p40, IL-15,IL-1 α ,MIP-1 β ,GMCSF,IFN- α 2,IL-10,VEGF and IL-R α were highly elevated in T2DM patients when non-diabetic healthy controls(a=10).(A)IL-6.1NF-a,GCSP,IL-12P40, IL-15,IL-1a,MINF-1p,GMCSP,1IN-42,IL-10,VFGF and IL-Kα were highly elevated in 12DM patients when compared to healthy controls and NDM patients. (B) IFN- $_{7}$, EGF and IL-8 were moderately elevated in T2DM patients when compared to healthy controls and NDM (D) Fotaxin was moderately elevated in healthy controls and NDM (D) Fotaxin was moderately elevated in healthy controls and NDM when compared to healthy controls and NDM (D) Eotaxin was moderately elevated in healthy controls and NDM when compared to healthy controls, MDC was elevated in NDM patients when compared to healthy controls, MDC was elevated in NDM patients when compared to healthy controls, MDC was elevated in NDM patients when compared to healthy controls, MDC was elevated in NDM patients when compared to healthy controls, MDC was elevated in NDM patients when compared to healthy controls, MDC was elevated in NDM patients when compared to healthy controls, MDC was elevated in NDM patients when compared to healthy controls, MDC was elevated in NDM patients when compared to healthy controls, MDC was elevated in NDM patients when compared to healthy controls. The Kruskal Wallis Test (non parametric) with post hoc Dunn's multiple comparison test was performed p<0.05 was considered statistically significant(***), P < 0.0001 was considered to be very significant (***), P < 0.0001 was considered extremely significant(***) ns, not significant. All error bars were SEM.

medRxiv preprint doi: https://doi.org/10.1101/2021.12.03.21267282; this version posted December 26, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .




Fig 3.Analysis of the circulating antibodies in T2DM ,NDM patients infected with SARS-CoV2 The bar diagram representing circulating antibody isotypes (IgA, IgM, IgG1, IgG2, IgG3,IgG4 and IgE) which were evaluated from COVID -19 positive plasma samples of T2DM(n=25), NDM(n=10) and Covid-19 negative and non-diabetic healthy controls(n=10). The Kruskal Wallis Test (non parametric) with with post hoc Dunn's multiple comparison test was performed p<0.05 was considered statistically significant (*), p<0.01 was considered to be very significant (**), P<0.0001 was considered to highly significant (***), P<0.0001 was considered extremely significant (****) ns, not significant. All error bars were SEM.




Fig 4.Innate Immune Cells in T2DM and NDM patients. Whole blood from Covid-19 positive T2DM(n=10), NDM(n=5) and Covid-19 negative and non-diabetic healthy controls (n=5)was stained heavy metal tagged antibody and analyzed in mass cytometer.(A)Representative Gating strategy to identify CD45⁺CD66ble^{tok} lymphocytes and CD45⁺CD66bl^{tok} foranulocytes. Statistical analysis of percentage of Granulocytes and lymphocytes.(B) Gating strategy for CD123⁺CD11c⁺ pDCs. Statistical analysis for the frequency of total DCs and pDCs.(C) Gating strategy for CD112⁺CD23^k mDCs.Statistical analysis for the frequency of basophils.(E) Gating strategy for MAIT/NKT cells. Statistical statistical statistical statistical analysis for the frequency of basophils.(E) Gating strategy for MAIT/NKT cells.) The Kruskal Wallis Test (non parametric) withwith post hoc Dunn's multiple comparison test was performed p<0.05 was considered statistical significant (***), *P* < 0.001 was considered to highly significant (***), *P* < 0.0001 was considered extremely significant (***) ns, not significant (***), *P* < 0.001 was considered to highly significant (***), *P* < 0.001 was considered to highly significant (***), *P* < 0.001 was considered to highly significant (***), *P* < 0.001 was considered to highly significant (***), *P* < 0.001 was considered to highly significant (***), *P* < 0.001 was considered to highly significant (***), *P* < 0.001 was considered statistical s

683

684

685




Fig 5.Adaptive Immune Cells in T2DM and NDM patients. Whole blood from Covid-19 positive T2DM(n=10), NDM(n=5) and Covid-19 negative and non-diabetic healthy controls (n=5)was stained heavy metal tagged antibody and analyzed in mass cytometer.(A)Representative Gating strategy to identify CD38° CD20° Plasmasblasts. Statistical analysis of percentage of plasmasblasts. **(B)** Gating strategy to identify CD45° CD3° CD4° and CD45° CD3° CD4° and CD45° CD3° CD4° and CD45° CD3° CD4° and CD45° CD3° CD4° Tells.(C) Gating strategy for CD4° CXCR3 CCR6° Th2 like cells. Statistical analysis for the percentage of Th2 like cells. (D) Gating strategy to identify CD45° CD27°). Statistical analysis for the percentage of Th2 like cells. Statistical analysis for the percentage of Th2 like cells. (D) Gating strategy to identify CD45° (CD27°). Statistical analysis for the percentage of Th2 like cells. Statistical analysis for the percentage of Th2 like cells. (D) Gating Strategy to identify CD45° (CD27°). Statistical analysis for the percentages of Th2 like cells. Statistical analysis for the percentages of Th2 like cells. CD27°). Statistical analysis for the percentages of Th2 like cells. CD27°) contracted to cells CD450° CD27°). Statistical analysis for the percentages of CD4° CA2° CCR6° CD27°) and CD4° EMCCR7°CD27°) and CD4° EMCCR7°CD27°). CB18° (CD4° CD27°). Statistical analysis for the percentages of the CD8° TE and EM cells The Kruskal Wallis Test (non parametric) with post hoc Duant's multiple comparison test was performed p<0.05 was considered statistical s

Ηġ Ε

૬ ⊬ક્રિટ્સ


688

687

-

. . . . 60 40

I:1 °



689

Fig.6 t-SNE analysis of lowest and highest expressed markers in T2DM patients. (A) CD8 and CD3 showing decreased expression in T2DM patients.(B) HLA-DR and CD 14 showing increased expression in T2DM patients when compared to controls

690

	T2DM	NDM	P VALUE
	n=25	n=10	
Age, median (IQR), years	46 (36-59)	49(40.25-55.50)	N. A
Sex, male/female, n (%)	17 (68%)/8(32%)	7 (70%)/3(10%)	N. A
Haemoglobin, gm/dl median (IQR)	12.2 (11.35-13.60)	14.25 (13.7-14.9)	0.0475
Platelets 10 ³ /µL median (IQR)	193 (154.5-235)	165 (159.5-197.5)	0.4027
White Blood Cells 10 ³ /μL, median (IQR)	6.1 (5.00-57.65)	5.8 (5.2-5.575)	0.4172
Neutrophils %, median (IQR)	75 (65.5-84)	55 (44.75-62)	0.0004
Lymphocytes%, median (IQR)	22 (15.5-29.75)	36 (26.75-39.75)	0.0349
Eosinophils %, median (IQR)	0	3 (3-4.5)	<0.0001
Monocytes%, median (IQR)	7 (5-9)	9 (8.5-10)	0.0373
D-dimer µg/mL, median (IQR)	0.45 (0.29-1.61)	0.19 (0.15-0.25)	0.0048
Ferritin ng/mL, median (IQR)	224.7 (145.9-464.1)	115 (110-289.5)	0.4975
Fasting Plasma Glucose mg/dL, median (IQR)	215 (142.72-244)	95.5 (88-101)	<0.0001
Hb1AC %, median (IQR)	6.9 (6-9)	N. T	N. A
CRP mg/mL, median (IQR)	69.62 (34.95-211)	13.28 (4.44-18.65)	0.0013
Serum SGOT U/L, median (IQR)	46.9 (30.2-64.6)	38 (30.75-43.25)	0.4432
Serum SGPT U/L, median (IQR)	27.6 (20-42)	40.5 (24.5-76.5)	0.1335

Table 1- Demographic details and laboratory findings of T2DM and NDM patients infected with SARS-CoV2

Hb1AC- Glycated haemoglobin, CRP- C-Reactive Protein, Serum SGOT-serum glutamic-oxaloacetic transaminase, Serum SGPT- serum glutamic-pyruvic transaminase, N.T-Not Tested, N.A-Not Applicable.